Patent ID: 11912776
Assignee: PFIZER INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 12:
13. A method of treating a condition associated with malignant cells expressing B-cell maturation antigen (BCMA) in a subject comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an engineered immune cell expressing at the surface a BCMA-specific chimeric CAR comprising an extracellular ligand-binding domain, a first transmembrane domain, and an intracellular signaling domain, wherein the extracellular ligand-binding domain comprises a single chain Fv fragment (scFv) comprising
(i) a VH region comprising a VH complementarity determining region 1 (VH CDR1), a VH complementarity determining region 2 (VH CDR2), and a VH complementarity determining region 3 (VH CDR3), wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 150, 151, or 152; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 153 or 154; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 155, and
a VL region comprising a VL complementarity determining region 1 (VL CDR1), a VL complementarity determining region 2 (VL CDR2), and a VL complementarity determining region 3 (VL CDR3), wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 209; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 221; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 222;
(ii) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 151, 156, or 157; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 158 or 159; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 155, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 209; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 221; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 225;
(iii) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 150, 151, or 152; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 187 or 188; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 155, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 249; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 221; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 225;
(iv) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 150, 151, or 152; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 165 or 166; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 155, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 226; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 221; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 227;
(v) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 150, 151, or 152; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 159 or 162; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 161, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 251; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 252; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 253;
(vi) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 151, 156, or 157; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 190 or 191; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 161, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 262; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 252; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 263;
(vii) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 150, 151, or 152; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 154 or 169; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 155, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 271; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 221; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 272;
(viii) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 129, 130, or 131; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 139 or 140; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 134, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 217; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 210; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 216; or
(ix) a VH region comprising a VH CDR1, a VH CDR2, and a VH CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 129, 130, or 131; the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 132 or 133; the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 137, and
a VL region comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 377; the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 210; the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 214,
wherein the transmembrane domain comprises a CD8α, chain transmembrane domain, and wherein the intracellular signaling domain comprises a CD3ξ signaling domain and/or a 4-1BB signaling domain.